Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven global pharmaceutical company, has launched India’s first topical Minocycline 4% Gel for the treatment of moderate to severe acne, under the brand name MINYM®. This is a potent antibacterial gel which exerts a strong anti-inflammatory action It also offers the lowest MIC90 (minimum Inhibitory Concentration at which it stops/prevents visible growth of 90% of isolates of bacteria) compared to the available topical antibacterial formulations.

Minym Gel

Topical antibacterial formulations are some of the commonly used class of drugs for the treatment of acne. With no new topical formulations being launched over the last 30 years, there has been a gradual increase in resistance to the currently available topical antibacterial formulations. MINYM® Gel (Topical Minocycline 4% Gel) has been developed to address these growing concerns in treatment of acne and is safe to use in patients above 9 years of age.

Acne is an inflammatory skin disease affecting millions of people worldwide. It involves the pilosebaceous units and presents with comedones, papules and pustules and is affected by numerous risk factors. Acne usually begins in puberty and affects many adolescents and young adults. In a study conducted by Glenmark in 2020, on the prevalence of acne in India, it was observed that 45 percent of the patients were males and 55 percent were females; and almost 72 percent of the patients were in the adolescent group whereas 27 percent patients were in the adult group.

Glenmark Pharmaceuticals launches MINYM® GEL – India’s First Topical Minocycline 4% Gel for the Treatment of Moderate to Severe Acne